Glaucoma Trials Tracker

Clinical Report: Overview of Active Interventional Glaucoma Trials

Overview

This report summarizes ongoing and recently completed interventional clinical trials targeting glaucoma treatment and management. The trials encompass novel surgical devices, pharmacologic agents, and innovative therapies aimed at lowering intraocular pressure and improving optic nerve health.

Background

Glaucoma is a leading cause of irreversible blindness worldwide, primarily managed by lowering intraocular pressure (IOP) to prevent optic nerve damage. Despite existing therapies, many patients experience progression, necessitating new treatment modalities. Current research includes evaluating minimally invasive surgical devices, novel drug formulations, and neuroprotective strategies to enhance efficacy and safety in glaucoma care.

Data Highlights

Trial Name	Sponsor	Status	Phase	Enrollment	Purpose
Ab Externo Approach for XEN45 Implantation	AbbVie	Completed	Not specified	Not specified	Assess disease activity change and adverse events
T4090 vs Rhopressa Ophthalmic Solution	Laboratoires Thea	Completed	Not specified	Not specified	Efficacy and safety assessment in open-angle glaucoma or ocular hypertension
VisiPlate Aqueous Shunt	Avisi Technologies Inc.	Active	Not specified	165	Evaluate safety and effectiveness in refractory open-angle glaucoma
Rocklatan Retinal Perfusion OCT Study	Oregon Health and Science University	Active	Phase 4	30	Assess effect of Rocklatan on ocular blood flow
QLS-111 Ophthalmic Solution (PENGUIN)	Qlaris Bio, Inc	Active	Phase 2	14	Evaluate effect on posterior perfusion and vessel dilation
ER-100 Safety Evaluation	Life Biosciences Inc	Active	Phase 1	18	Safety and tolerability in glaucoma and optic neuropathies
Brimonidine Tartrate 0.025% Injection	Insight Eyecare Specialties, Inc	Active	Phase 4	35	Effect on conjunctival hyperemia with netarsudil/latanoprost therapy
Topical Insulin for Glaucoma	Stanford University	Active	Phase 1	52	Safety of topical recombinant insulin in optic neuropathies
BL1107 Eye Drops vs Timolol	Bausch + Lomb Inc.	Active	Phase 2	228	Safety and efficacy in primary open-angle glaucoma or ocular hypertension
NT-501 Encapsulated Cell Therapy	Stanford University	Active	Phase 2	30-60	Neuroprotection and vision restoration in glaucoma
Retinal Blood Flow and Autoregulation	University of Maryland	Active	Phase 4	90	Establish retinal blood flow autoregulation as biomarker for glaucoma
iStent Infinite and iDose TR	Glaukos Corporation	Active	Phase 4	20	Evaluate minimally invasive surgical and drug depot options for IOP reduction
Travoprost Intracameral Implant	Glaukos	Active	Phase 2/3	610	Safety and efficacy evaluation of second generation implant
Pilocarpine Use After Kahook Goniotomy	Montefiore Medical Center	Active	Phase 3	142	Assess added benefit of pilocarpine post combined cataract and KDB surgery
PER-001 Intravitreal Implant	Perfuse Therapeutics, Inc.	Active	Phase 1/2a	36	Safety, tolerability, and pharmacodynamics in open-angle glaucoma
Simbrinza and Rocklatan vs Cosopt and Latanoprost	Prairie Eye Center	Active	Phase 4	70	Comparative efficacy in mild to moderate open-angle glaucoma

Key Findings

Multiple novel surgical devices such as VisiPlate aqueous shunt and iStent infinite are under investigation for refractory and moderate to severe open-angle glaucoma.
New pharmacologic agents including T4090, BL1107, and PER-001 are being evaluated for safety and efficacy compared to established therapies like timolol and Rhopressa.
Neuroprotective strategies such as NT-501 encapsulated cell therapy and topical insulin are being explored to preserve optic nerve function and improve vision outcomes.
Studies are assessing ocular blood flow and retinal perfusion changes with agents like Rocklatan and QLS-111 to understand vascular contributions to glaucoma progression.
Phase 4 trials are investigating adjunctive treatments such as brimonidine tartrate to reduce side effects like conjunctival hyperemia in combination therapies.
Large enrollment trials, including a 610-participant study on travoprost intracameral implants, highlight the scale of ongoing research efforts.

Clinical Implications

Clinicians should be aware of emerging minimally invasive surgical options and novel pharmacotherapies that may soon expand treatment choices for glaucoma patients. Understanding ongoing research on neuroprotection and vascular modulation may inform future therapeutic strategies. Monitoring trial outcomes will be essential to integrate new evidence-based interventions into practice.

Conclusion

The current landscape of glaucoma clinical trials demonstrates a robust pipeline of innovative treatments targeting multiple disease mechanisms. Continued research is critical to improving patient outcomes and addressing unmet needs in glaucoma management.

References

Glaucoma Trials Tracker -- ClinicalTrials.gov

PentaVision

Glaucoma Physician